EUVIMEDEUVIMED entdecken
Kommentar

In patients with HFpEF and obesity, semaglutide increased weight loss and reduced symptoms and physical limitations at 52 wk

Hyeon-Ju Ali, Anita Deswal

Annals of Internal Medicine · 2023

DOI: 10.7326/j23-0101 ↗

Kurz gefasst

Kommentar in der Zeitschrift Annals of Internal Medicine, 2023. Verfasst von Hyeon-Ju Ali und 1 weiteren Autor:innen. Beteiligte Einrichtung: University of Texas MD Anderson Cancer Center, Houston, Texas, USA (H.A., A.D.). Hauptthemen laut MEDLINE: Heart Failure. Die Arbeit wurde bisher 4-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart FailureHumansStroke VolumeObesityWeight GainWeight LossSemaglutide

Substanzen

Semaglutide

Autor:innen und Institutionen

  • University of Texas MD Anderson Cancer Center, Houston, Texas, USA (H.A., A.D.).

Zitieren

APA

Ali, H. J., & Deswal, A. (2023). In patients with HFpEF and obesity, semaglutide increased weight loss and reduced symptoms and physical limitations at 52 wk. Annals of Internal Medicine. https://doi.org/10.7326/j23-0101

Vancouver

Ali HJ, Deswal A. In patients with HFpEF and obesity, semaglutide increased weight loss and reduced symptoms and physical limitations at 52 wk. Annals of Internal Medicine. 2023. doi:10.7326/j23-0101

BibTeX
@article{Ali2023,
  author = {Ali, Hyeon-Ju and Deswal, Anita},
  title = {In patients with HFpEF and obesity, semaglutide increased weight loss and reduced symptoms and physical limitations at 52 wk},
  journal = {Annals of Internal Medicine},
  year = {2023},
  doi = {10.7326/j23-0101}
}
Kostenlos starten →